Introduction: Impurity research of cardiovascular drugs: from "large quantity" to "high quality"
Cardiovascular disease has long ranked first among global causes of death, and the market scale of related drugs is huge. From classic β-receptor blockers to first-line antihypertensive and lipid-lowering drugs, there are numerous varieties with high output and a broad patient population, imposing strict requirements on impurity research: challenges in isomer separation caused by dense chiral centers, complex photodegradation and oxidative degradation pathways, and continuous regulatory attention on nitrosamine toxic impurities in recent years. The completeness of impurity reference standards is directly related to the progress of drug quality research and registration applications.
As a professional supplier deeply engaged in the field of impurity reference standards, Sinco focuses on four core cardiovascular drugs in this issue, covering impurity items of Metoprolol, Carteolol, Atorvastatin, and Amlodipine, providing a full set of compliant spectra to offer traceable reference support for your impurity research.
Star Products of This Issue
β1-receptor blocker: Metoprolol Impurities
【Common Challenges】
Contains chiral centers; secondary amines are prone to oxidation to form N-oxides; regulations on nitrosamine toxic impurities such as N-nitrosometoprolol continue to tighten, with increasingly strict limit control requirements.
【Sinco Offers】
A total of 32 related impurity structures, with a full set of structural confirmation spectra (including COA, NMR, MS, HPLC, etc.) available, supporting impurity profiling of nitrosamine toxic impurities.
Non-β1-receptor blocker: Carteolol Impurities
【Common Challenges】
Contains chiral centers, with strict requirements for enantiomeric purity control; the quinolone skeleton involves multiple steps in synthesis, resulting in a complex impurity profile of process intermediates and by-products.
【Sinco Offers】
A total of 36 related impurity structures, with a full set of compliant spectra available, providing compliant reference standard support for enantiomeric purity control and impurity quantification.
HMG-CoA Reductase Inhibitor: Atorvastatin Impurities
【Common Challenges】
Contains multiple chiral centers, with numerous diastereomers that are difficult to separate; the lactone ring opening/closing equilibrium causes the impurity profile to change dynamically with conditions; the pyrrole ring is prone to oxidative degradation; fluorine-containing structures increase the difficulty of identifying process impurities.
【Sinco Offers】
A total of 68 related impurity structures, with a full set of analytical spectra available, facilitating chiral method development, transfer, and system suitability confirmation.
Dihydropyridine Calcium Channel Blocker: Amlodipine Impurities
【Common Challenges】
The dihydropyridine ring is extremely photosensitive, and pyridine-type photodegradation impurities are easily generated under light; contains chiral carbon atoms, with strict control of R/S enantiomeric impurities; the aminoethoxymethyl side chain is prone to hydrolysis under acidic/alkaline conditions; significant differences exist in the impurity profiles of processes using besylate and maleate salt forms.
【Sinco Offers】
A total of 80 related impurity structures, with a full set of authoritative spectra available, supporting resolution investigation and qualitative/quantitative research of chiral impurities.
Why Choose Sinco?
✅ Compliance Foundation: CQC certification + full set of structural confirmation spectra, with a complete data chain.
✅ Independent Synthesis: A self-developed library of over 30,000 compounds, tackling the customization of high-difficulty impurities.
✅ Efficient Delivery: 24-hour response, 2-4 working days delivery for in-stock items, trusted by customers in 40 countries worldwide.